Pure FECO Oil in glass bottle (60ml)
In 2026, the use of 60ml (or 60 gram) FECO concentrate in a glass bottle is widely recognized as the standard "Full Cycle" for the Rick Simpson Protocol. This specific volume is designed to provide a 90-day treatment window, allowing the patient to titrate from a micro-dose to a full gram per day.
1. The 60ml Protocol Strategy (90 Days)
The goal of this protocol is to saturate the body’s endocannabinoid system to a level where it can potentially induce autophagy (programmed cell death) in mutated cells, while managing the intense side effects of traditional oncology treatments.
Phase 1: Induction (Weeks 1–3): Patients start with a dose the size of half a grain of rice (20 - 30mg) three times a day.
Phase 2: Titration (Weeks 4–5): The dose is doubled every 4 days. The body builds a "functional tolerance," allowing the patient to handle high levels of THC without extreme impairment.
Phase 3: Saturation (Weeks 6–12): The patient reaches the goal of consuming 1 gram (approx. 1ml) per day. This is where the bulk of the 60ml concentrate is utilized.
Phase 4: Maintenance: After the 60ml is finished, patients typically drop to a "maintenance dose" of 1–2 grams per month to keep the immune system primed.
2. Benefits of Glass Bottle Storage (2026 Standards)
In 2026, clinical-grade FECO is almost exclusively dispensed in Miron (Violet) Glass or high-quality borosilicate glass for several critical reasons:
Terpene Preservation: Glass is non-porous and chemically inert. Plastic can "leach" monoterpenes like Pinene and Limonene, which are vital for the anti-tumor "entourage effect."
BPA & Phthalate Prevention: High-potency lipids (oils) can degrade plastic over time. Storing a 90-day supply in glass ensures no microplastics or endocrine disruptors contaminate the medicine.
UV Protection: Dark glass (amber or violet) blocks UV rays that would otherwise convert THC into CBN, turning a potent anti-cancer oil into a purely sedative one.
Stability for Heating: FECO is highly viscous. A glass bottle allows the patient to safely warm the container in a "warm water bath" to make the oil flowable without fear of chemicals leaching from the container.
Therapeutic Targets in the Cancer Protocol
| Benefit | Mechanism of Action (2026 Data) |
|---|---|
| Anti-Angiogenesis | Cannabinoids inhibit the "VEGF" pathway, potentially starving tumors of new blood supply. |
| CINV Management | Blocks serotonin signals in the brainstem to stop Chemotherapy-Induced Nausea and Vomiting. |
| Cytokine Regulation | FECO reduces systemic inflammation (IL-6), which often drives cancer-related fatigue. |
| Appetite Stimulation | Triggers the release of Ghrelin, essential for fighting "Cachexia" (muscle wasting). |
3. Administration and Bioavailability
For a 60ml protocol, 2026 guidelines recommend the "Lipid-Bridge" method:
The Medium: Because FECO is fat-soluble, taking it with a spoonful of coconut oil or avocado increases absorption by up to 4x.
The Route: For many cancers, Rectal Administration (using the FECO to make suppositories) is preferred. This bypasses "First-Pass Metabolism" in the liver, allowing for higher blood saturation with significantly less psychoactive "high."
2026 Safety Warning
The 1-Gram Ceiling: Consuming 1 gram of FECO daily is a massive physiological load. In 2026, it is strictly advised to monitor Liver Enzymes (ALT/AST) and Blood Pressure.
